E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10039073 |
E.1.2 | Term | Rheumatoid arthritis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare (i) baseline characteristics and (ii) changes over time in a) Ultrasonographic imaging of a discrete joint set including the joints selected for synovial biopsy b) Synovial tissue histology and immunohistochemistry (inflammation and phosphoprotein markers) c) Peripheral blood biomarkers of inflammation and tissue repair. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to investigate the relationship between synovial pathology and ultrasonographic imaging parameters and to explore possible correlations between clinical efficacy and biologic effects of anti-TNF therapy on peripheral blood and synovial tissue biomarkers. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria: Group A Only 1a. Naïve to either etanercept or adalimumab, or who may have received prior anti-TNF therapy and displayed an intolerance but is now considered to be appropriate candidate for treatment with either etanercept or adalimumab.
Inclusion Criteria: Group B Only 1b. History (as documented in the patient’s medical records) of initial clinical response to either etanercept or adalimumab and a subsequent loss of clinical response. Initial clinical response is defined as attainment of Good or Moderate response by EULAR criteria during the first 3 months of anti-TNF therapy; the consistency of the response must be documented on at least two consecutive occasions separated by at least 4 weeks. Loss of response to therapy is defined as DAS 28 score ≥ 4.5 and increase or worsening in DAS 28 by ≥ 1.2 from lowest DAS achieved on anti-TNF therapy, in at least two consecutive evaluations separated by at least 4 weeks. A documented loss of response is required prior to study screening. Confirmation of loss of response will occur at the Screening Visit.
Inclusion Criteria: Groups A and B
Able and willing to give written informed consent and comply with the requirements of the study protocol. Diagnosis of RA at least 3 months prior to start of anti-TNF therapy, according to the revised 1987 ACR criteria. Age 18–80 years, inclusive. If on corticosteroids, dose must be ≤ 10 mg prednisone (or equivalent) for at least 2 weeks prior to baseline assessment. Must have inadequate response to MTX at a dose of 10-25 mg/week (po or parenteral) for ≥ 12 weeks, of which the 4 weeks immediately prior to the baseline visit have been at a stable dose. Swollen joint count (SJC) ≥ 4 (28 joint count), and tender joint count (TJC) ≥ 4 (28 joint count) at baseline. At screening, either; CRP ≥ 0.6 mg/dL (6 mg/L) with high sensitivity assay OR ESR ≥ 28 mm/h. At least one active joint that is appropriate for biopsy. Positive for rheumatoid factor (RF) or anti-CCP. If female, and of child bearing potential, must agree to use a reliable form of contraception (eg.hormonal contrceptive, patch, intra-uterine device, physical barrier) during the study and for 5 months following the last dose of prescribed anti-TNF therapy. If male, must agree to use(with his partner) a reliable form of contraception (hormonal contrceptive, patch, intra-uterine device, physical barrier method), during the study and for 5 months following the last dose of prescribed anti-TNF therapy |
|
E.4 | Principal exclusion criteria |
Exclusion Criteria: Groups A and B Patients with any of the following will be excluded from the study: Any contraindication for entanercept or adalimumab treatment according to the approved product label. Pregnant or Breast feeding History of or current inflammatory joint disease or autoimmune disease other than RA. Treatment with sulfasalazine, hydroxychloroquine, chloroquine,D-penicillamine, auranofin, azathioprine, cyclosporine, or tacrolimus ≤ 4 weeks prior to baseline, or abatacept or leflunomide ≤ 8 weeks before baseline. Treatment with any investigational agent ≤ 4 weeks prior to baseline or < 5 half-lives of the investigational drug or where persisting PD effect (eg, cell depletion) of investigational therapy on target cells or pathways to RA (whichever is longer). Previous treatment with alkylating agents or cell-depleting therapies, including investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti-CD11a, Blys, BAFF, anti-CD22 and anti-CD20). Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline. Intra-articular or parenteral corticosteroids ≤ 2 weeks prior to baseline. Intra-articular treatment of the joint selected for biopsy within 3 months of baseline visit. History of heart failure. Evidence of significant uncontrolled concomitant diseases such as neurological, cardiovascular, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the investigator, would preclude patient participation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
to compare (i) baseline characteristics and (ii) changes over time in: a) Ultrasonographic imaging of a discrete joint set including the joints selected for synovial biopsy b) Synovial tissue histology and immunohistochemistry (inflammation and phosphoprotein markers). c) Peripheral blood biomarkers of inflammation and tissue repair. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |